Targeting EP2 receptors to improve treatment for ischemic stroke
EP2 Antagonists for Ischemic Stroke
This study is looking at new medications that could help people who have had an ischemic stroke by targeting a specific part of the brain involved in inflammation and injury, with the goal of finding safer and more effective treatments to use right after a stroke happens.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Health Sci Ctr NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project ID | NIH-10907027 on NIH RePORTER |
What this research studies
This research investigates the role of EP2 antagonists in treating ischemic stroke, a condition that affects a significant number of adults and can lead to severe disabilities or death. The study aims to develop new medications that can safely target the EP2 receptor, which is involved in brain inflammation and injury following a stroke. By focusing on this specific pathway, the researchers hope to create more effective treatments that can be administered within the critical time window after a stroke occurs. The approach involves understanding the biochemical mechanisms of stroke and testing new drug candidates that can penetrate the brain effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults who have experienced an ischemic stroke or are at risk of having one.
Not a fit: Patients who have other types of strokes, such as hemorrhagic strokes, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for patients suffering from ischemic stroke.
How similar studies have performed: Previous research has shown promise in targeting inflammatory pathways in stroke treatment, suggesting that this approach could be a meaningful advancement.
Where this research is happening
Memphis, United States
- University of Tennessee Health Sci Ctr — Memphis, United States (Active)
Researchers
- Principal investigator: Jiang, Jianxiong — University of Tennessee Health Sci Ctr
- Study coordinator: Jiang, Jianxiong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.